亞洲 疫苗
疫苗：亞洲疫苗廠從供應本國，走向下一代新疫苗。
8追蹤資產
4已核准
已核准最高階段
最新事件日期
這個賽道在做什麼
疫苗在感染發生前先訓練免疫系統，所以要在大量健康的人身上測試，安全性和效果一樣重要。中國有龐大的本土疫苗產業，肺炎鏈球菌、HPV、流感與帶狀疱疹疫苗現在都能自己生產，不再依賴進口。下一步是涵蓋範圍更廣的設計與重組疫苗，也有計畫和國際藥廠共同開發，例如 SK bioscience 與賽諾菲合作的肺炎鏈球菌疫苗。
階段分布
已核准4
申請／審查2
第三期2
國家分布
中國7 7
韓國1 1
資產表
| 排名 | 資產 | 國際非專利名稱 | 原研公司 | 國家 | 標的 | 機轉 | 最高階段 | 適應症 | 試驗登錄號 | 海外權利人 | 交易日期 | 首付款 | 總額上限 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tripecia | Not disclosed | CanSino Biologics | China | Diphtheria; tetanus; Bordetella pertussis | Adsorbed diphtheria-tetanus-acellular pertussis combination vaccine | Approved — China (2026-04) | Prevention of diphtheria, tetanus and pertussis in children | NCT05951725 | None reported | — | — | — | Company update confirms Tripecia as an approved three-component acellular pertussis vaccine | 2026-10-27 | 1 2 3 | 2026-10-27 |
| 2 | iPneucia | Not disclosed | CanSino Biologics | China | Streptococcus pneumoniae (13 serotypes) | 13-valent pneumococcal conjugate vaccine | Approved — China (2025-06) | Prevention of pneumococcal disease in infants and children | NCT04841369 | None reported | — | — | — | Company announces NMPA marketing approval for its PCV13i vaccine | 2025-06-20 | 1 2 | 2025-06-20 |
| 3 | Cecolin 9 | Not disclosed | Xiamen Innovax Biotech / Xiamen University | China | HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 | Recombinant nine-valent HPV virus-like-particle vaccine | Approved — China (2025-05) | Prevention of disease associated with nine HPV types | Not disclosed | None reported | — | — | — | Manufacturer confirms Cecolin 9 approval in Thailand during 2026; exact approval date not disclosed | 2026-10-21 | 1 2 3 4 | 2026-10-21 |
| 4 | Zhifei quadrivalent influenza vaccine | Not disclosed | Anhui Zhifei Biopharmaceutical / Chongqing Zhifei Biological Products | China | Influenza A and B viruses | Inactivated quadrivalent split-virion influenza vaccine | Approved — China (2025-03) | Prevention of influenza in adults and children aged 3 years and older | Not disclosed | None reported | — | — | — | Company announces receipt of NMPA registration certificate for its quadrivalent influenza vaccine | 2025-03-21 | 1 2 | 2025-06-05 |
| 5 | REC610 | Not disclosed | Jiangsu Recbio Technology | China | Varicella-zoster virus glycoprotein E | Adjuvanted recombinant herpes zoster vaccine | Registration — China (confirmed 2026-09; marketing-application stage) | Prevention of herpes zoster in adults aged 40 years and older | Not disclosed | None reported | — | — | — | 2026 interim report confirms marketing-application stage following phase 3 development | 2026-09-23 | 1 2 | 2026-09-23 |
| 6 | LZ901 | Not disclosed | Beijing Luzhu Biotechnology | China | Varicella-zoster virus | Recombinant herpes zoster vaccine | Registration — China (2025-02; BLA accepted; approval not established) | Prevention of herpes zoster | NCT06088745 | None reported | — | — | — | Company reports publication of phase 3 results; its product page states BLA review remains ongoing | 2026-08-07 | 1 2 3 4 | 2026-08-07 |
| 7 | GBP410 | Not disclosed | SK bioscience / Sanofi | South Korea | Streptococcus pneumoniae (21 serotypes) | 21-valent pneumococcal conjugate vaccine | Phase 3 — global (confirmed 2026-09; underway) | Prevention of pneumococcal disease in children | Not disclosed | Sanofi (co-development partner; commercialisation outside South Korea); SK bioscience (South Korea) | 2024-12-23 | Not disclosed (GBP410-specific allocation) | Not disclosed | Sanofi Q3 2026 pipeline reports phase 3 SP0202 and identifies SK bioscience as its partner; snapshot as of September 30 | 2026-10-30 | 1 2 3 | 2026-10-30 |
| 8 | REC603 | Not disclosed | Jiangsu Recbio Technology | China | HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 | Recombinant nine-valent HPV virus-like-particle vaccine | Phase 3 — China (confirmed 2026-09; ongoing follow-up) | Prevention of HPV-related disease | Not disclosed | None reported | — | — | — | 2026 interim report retains REC603 in phase 3 clinical development | 2026-09-23 | 1 2 | 2026-09-23 |